Network elevates standard of care for Canadians living with Crohn's disease and ulcerative colitis
TORONTO, May 11, 2016 /CNW/ - Crohn's and Colitis Canada proudly introduces the country's first national network of leading Crohn's disease and ulcerative colitis patient care and research centres. Promoting Access and Care through Centres of Excellence (PACE) is the largest Canadian collaboration for adults living with Crohn's disease and ulcerative colitis, the two main forms of inflammatory bowel disease (IBD).
"PACE unites centres of excellence to combine areas of expertise. It is a bold step forward to close gaps in Crohn's disease and ulcerative colitis care," says Mina Mawani, President and Chief Executive Officer, Crohn's and Colitis Canada. "Working together, we will reduce chronic steroid use, expand access to inflammatory bowel disease specialists, empower patients and improve long-term outcomes."
The PACE model is unique for Crohn's and colitis care in Canada. PACE will facilitate a combination of independent research and collaborative learning over a four-year period. During the first year, each centre of excellence will drive its own research. The centres will then work collaboratively in order to develop their own competencies in all areas.
Recognizing the current gaps in care, Crohn's and Colitis Canada chose to invest in five centres to support patient care. Together, they selected Dr. Geoffrey Nguyen, Clinician Scientist at Mount Sinai Hospital's Centre of Excellence for Inflammatory Bowel Disease, which has one of Canada's largest and most comprehensive multidisciplinary team of IBD clinicians, to spearhead PACE.
"We have the opportunity to better serve the quarter of a million Canadians living with Crohn's disease and ulcerative colitis," he says. "PACE provides a platform to share and strengthen our knowledge in order to improve patient outcomes."
Dr. Nguyen is also one of the expert clinicians leading the centres in three provinces.
Mount Sinai Hospital, part of Sinai Health System, Toronto ON – Geoffrey Nguyen, MD, PhD, FRCPC
"Our centre is leveraging the Ontario Telemedicine Network's infrastructure and resources to access remote communities and extend the reach of our specialized care. We see ourselves pioneering this novel technology in the IBD field," says Nguyen.
University of Calgary, Calgary AB – Remo Panaccione, MD, FRCPC
"Our priority is reducing chronic steroid use in Crohn's disease and ulcerative colitis patients. Three quarters of patients referred to a specialist are on steroid treatment and our work addresses this issue," says Panaccione, a member of the Snyder Institute for Chronic Diseases and Department of Medicine at the Cumming School of Medicine.
University of Alberta, Edmonton AB – Richard Fedorak, MD, FRCPC, FRCP (London), FRSC
"We are introducing technology to integrate best practices into the healthcare system to ensure all patients are getting the best care," says Fedorak.
McMaster University, Hamilton ON – John Marshall, MD, MSc, FRCPC and Dr. Neeraj Narula, MD, FRCPC
"The doctor and patient time is far more productive when patients monitor their own health in between visits," says Marshall. "Empowering patients ultimately leads to better adherence to treatments, informed discussions and improved monitoring of high-risk cases," he adds.
McGill University Health Centre (MUHC), Montreal QC – Alain Bitton, MD, FRCPC
"This level of collaboration will be monumental for IBD care. We are combining data from across the country which allows us to evaluate the success of each PACE network in order to advocate for improved healthcare delivery," says Bitton.
Crohn's and Colitis Canada, along with its partners AbbVie Corporation, Janssen Inc. and Takeda Canada, are investing an initial $2.5 million over four years. Over time, PACE plans to add more centres of excellence to the network and share its findings across IBD healthcare providers to ensure learnings will benefit all Crohn's and colitis patients.
About Crohn's and Colitis Canada
Crohn's and Colitis Canada is the only national, volunteer-based charity focused on finding the cures for Crohn's disease and ulcerative colitis and improving the lives of children and adults affected by these chronic diseases. We are one of the top two health charity funders of Crohn's and colitis research in the world, investing over $94 million in research to date. We are transforming the lives of people affected by Crohn's and colitis (the two main forms of inflammatory bowel disease) through research, patient programs, advocacy, and awareness. Our Crohn's & Colitis – Make it stop. For life. Campaign will raise $100 million by 2020 to advance our promise.
SOURCE Crohn's & Colitis Canada
Image with caption: "Crohn's & Colitis Canada (CNW Group/Crohn's & Colitis Canada)". Image available at: http://photos.newswire.ca/images/download/20160511_C3181_PHOTO_EN_687895.jpg
For further information: or to arrange an interview with a representative of Crohn's and Colitis Canada, a research clinician or patient, please contact: Nic Canning, Smithcom Ltd., Account Manager, [email protected], 413-992-7187; Tyler Simpson, Crohn's and Colitis Canada, Marketing & Communications Coordinator, [email protected], 416-920-5035, ext. 215